IMUNA PHARM — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IMUNA PHARM is a long-established Slovak biopharmaceutical company with a dual focus on innovative immunotherapies for oncology and a commercial portfolio of disinfectants and pharmaceutical products. Leveraging its GMP-certified manufacturing infrastructure, the company aims to develop advanced immunological treatments while maintaining a revenue-generating base business. Its strategic position in Central Europe provides a platform for both regional commercial operations and R&D targeting global healthcare challenges in cancer and infectious diseases.

OncologyImmunology

Technology Platform

Advanced immunological approaches for cancer treatment, leveraging potential expertise in immunomodulation. Supported by GMP-certified manufacturing infrastructure.

Opportunities

The growing global immunotherapy market in oncology presents a major high-value opportunity.

Additionally, the company's GMP-certified manufacturing and established disinfectant product line provide a stable revenue base and platform for expansion in healthcare hygiene markets.

Risk Factors

High R&D risk associated with developing novel immunotherapies in a fiercely competitive landscape.

Dependency on commercial product sales for funding, which may be insufficient for costly late-stage clinical trials.

Potential challenges in scaling scientific and commercial operations internationally.

Competitive Landscape

In oncology R&D, IMUNA PHARM competes with global biopharma giants and well-funded biotechs. In its commercial business, it competes with other regional pharmaceutical manufacturers and large multinational producers of disinfectants and hygiene products.

More companies in Europe - Other →